CLSD / Clearside Biomedical, Inc. - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

FORM 8-K Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. Item 5.07 Submission of Matters to a Vote of Security Holders.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 28, 2025 Clearside Biomedical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37783 45-2437375 (State or Other Jurisdiction of Incorporation) (Commiss

FORM 8-K Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrange

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2025 Clearside Biomedical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37783 45-2437375 (State or Other Jurisdiction of Incorporation) (Commiss

Separation Agreement, by and between Registrant and George Lasezkay, dated as of July 17, 2025.

Exhibit 10.1 July 17, 2025 Via Email George Lasezkay Re: Separation Agreement Dear George: This letter sets forth the substance of the separation agreement (the “Agreement”) which Clearside Biomedical, Inc. (the “Company”) is offering to you to aid in your employment transition. 1. Separation Date. Your last day of work with the Company and your employment termination date will be July 18, 2025 (t

Separation Agreement, by and between Registrant and Victor Chong, dated as of July 17, 2025.

Exhibit 10.5 July 17, 2025 Via Email Victor Chong Re: Separation Agreement Dear Victor: This letter sets forth the substance of the separation agreement (the “Agreement”) which Clearside Biomedical, Inc. (the “Company”) is offering to you to aid in your employment transition. 1. Separation Date. Your last day of work with the Company and your employment termination date will be July 18, 2025 (the

Consulting Agreement, by and between Registrant and Charles Deignan, dated as of July 17, 2025.

Exhibit 10.4 Consulting Agreement This Consulting Agreement (the “Consulting Agreement”) by and between Clearside Biomedical, Inc. (“Client”) and Charlie Deignan, an individual (“Consultant”) is effective as of July 18, 2025 (the “Consulting Agreement Effective Date”), subject to the terms of Section 14 below. RECITALS WHEREAS the parties desire for the Client to engage Consultant to perform the s

Consulting Agreement, by and between Registrant and George Lasezkay, dated as of July 17, 2025.

Exhibit 10.2 Consulting Agreement This Consulting Agreement (the “Consulting Agreement”) by and between Clearside Biomedical, Inc. (“Client”) and George Lasezkay, an individual (“Consultant”) is effective as of July 18, 2025 (the “Consulting Agreement Effective Date”), subject to the terms of Section 14 below. RECITALS WHEREAS the parties desire for the Client to engage Consultant to perform the s

Consulting Agreement, by and between Registrant and Victor Chong, dated as of July 17, 2025.

Exhibit 10.6 Consulting Agreement This Consulting Agreement (the “Consulting Agreement”) by and between Clearside Biomedical, Inc. (“Client”) and Victor Chong, an individual (“Consultant”) is effective as of July 18, 2025 (the “Consulting Agreement Effective Date”), subject to the terms of Section 14 below. RECITALS WHEREAS the parties desire for the Client to engage Consultant to perform the serv

Separation Agreement, by and between Registrant and Charles Deignan, dated as of July 17, 2025.

Exhibit 10.3 July 17, 2025 Via Email Charlie Deignan Re: Separation Agreement Dear Charlie: This letter sets forth the substance of the separation agreement (the “Agreement”) which Clearside Biomedical, Inc. (the “Company”) is offering to you to aid in your employment transition. 1. Separation Date. Your last day of work with the Company and your employment termination date will be July 18, 2025 (

At the Company's 2025 annual meeting of stockholders held on May 30, 2025, the Company's stockholders approved an amendment to the Company's Amended and Restated Certificate of Incorporation to increase the Company's authorized number of shares of co

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37783 Clearside Biomedical, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defi

FORM 8-K Item 2.05 Costs Associated with Exit or Disposal Activities. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Item 8.01 Other Events.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 17, 2025 Clearside Biomedical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37783 45-2437375 (State or Other Jurisdiction of Incorporation) (Commissio

Clearside Biomedical Announces Plan to Explore Strategic Alternatives to Advance its Proprietary Suprachoroidal Space (SCS®) Delivery Platform and Promising Ophthalmology Pipeline - Proven In-Office, Repeatable, Non-Surgical Procedure for the Targete

Exhibit 99.1 Clearside Biomedical Announces Plan to Explore Strategic Alternatives to Advance its Proprietary Suprachoroidal Space (SCS®) Delivery Platform and Promising Ophthalmology Pipeline - Proven In-Office, Repeatable, Non-Surgical Procedure for the Targeted Delivery of a Wide Variety of Therapies for Serious Retinal Diseases - - CLS-AX Phase 3-Ready Asset with Global Investigator Support an

Certificate of Amendment to Amended and Restated Certificate of Incorporation (incorporated herein by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K (File No. 001-37783) filed with the SEC on May 30, 2025).

Exhibit 3.1 CERTIFICATE OF AMENDMENT TO AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF CLEARSIDE BIOMEDICAL, INC. Clearside Biomedical, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “DGCL”), certifies: FIRST: The name of the corporation is Clearside Biomedical, Inc. (the “Company”). SECOND: The Company’s original C

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 30, 2025 Clearside Biomedical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37783 45-2437375 (State or Other Jurisdiction of Incorporation) (Commission

The Company’s amended and restated certificate of incorporation authorizes the Company to issue 200,000,000 shares of $0.001 par value common stock. As of March 31, 2025 and December 31, 2024, there were 77,272,786 and 76,578,383 shares of common sto

May UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37783 Clearside Biomedical, Inc.

Filing Fee Table.

Exhibit 107 Calculation of Filing Fee Table Form S-8 CLEARSIDE BIOMEDICAL, INC. (Exact name of Registrant as specified in its charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, par value $0.001 p

As filed with the Securities and Exchange Commission on May 15, 2025

As filed with the Securities and Exchange Commission on May 15, 2025 Registration No.

Clearside Biomedical Announces First Quarter 2025 Financial Results and Provides Corporate Update - Successful End-of-Phase 2 Meeting with FDA Led to Alignment on Phase 3 Program Design for CLS-AX in Wet AMD - - CLS-AX Targets Commercially Attractive

Exhibit 99.1 Clearside Biomedical Announces First Quarter 2025 Financial Results and Provides Corporate Update - Successful End-of-Phase 2 Meeting with FDA Led to Alignment on Phase 3 Program Design for CLS-AX in Wet AMD - - CLS-AX Targets Commercially Attractive Product Profile with Three-to-Six Month Flexible Maintenance Dosing - - Multiple Milestones Achieved by Commercial and Development Partn

FORM 8-K Item 2.02 Results of Operations and Financial Condition. Item 9.01 Financial Statements and Exhibits.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2025 Clearside Biomedical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37783 45-2437375 (State or Other Jurisdiction of Incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ý Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State

Clearside Biomedical, Inc. Amended and Restated Insider Trading Policy.

Exhibit 19 Clearside Biomedical, INC. Insider Trading Policy As Amended and Restated on March 24, 2025 I. Introduction This policy determines acceptable transactions in the securities of Clearside Biomedical, Inc. (the “Company”) by our employees, directors and consultants. During the course of your employment, directorship or consultancy with the Company, you may receive important information tha

Clearside Biomedical Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - Successful End-of-Phase 2 Meeting with FDA Results in Alignment on Phase 3 Plans for CLS-AX in Wet AMD - - Asia-Pacific Partner’s New D

Exhibit 99.1 Clearside Biomedical Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - Successful End-of-Phase 2 Meeting with FDA Results in Alignment on Phase 3 Plans for CLS-AX in Wet AMD - - Asia-Pacific Partner’s New Drug Application for ARCATUS® (XIPERE®) for Uveitic Macular Edema Accepted for Regulatory Review in China - - Multiple Medical Meeting Pre

Forward-Looking Statements This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “int

Corporate Presentation March 2025 Exhibit 99.2 Forward-Looking Statements This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” or the negative of

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37783 Clearside Biomedical, Inc.

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2025 Clearside Biomedical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37783 45-2437375 (State or Other Jurisdiction of Incorporation) (Commissi

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 07, 2025 Clearside Biomedical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37783 45-2437375 (State or Other Jurisdiction of Incorporation) (Commi

Regulation FD Disclosure, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 12, 2024 Clearside Biomedical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37783 45-2437375 (State or Other Jurisdiction of Incorporation) (Commi

Forward-Looking Statements This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “int

Investor Presentation December 2024 Exhibit 99.1 Forward-Looking Statements This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” or the negative

Clearside Biomedical Announces Third Quarter 2024 Financial Results and Provides Corporate Update - Recent ODYSSEY Phase 2b Trial of Suprachoroidal CLS-AX in Wet AMD Achieved All Primary and Secondary Outcomes - - Positive Topline Results Support Adv

Exhibit 99.1 Clearside Biomedical Announces Third Quarter 2024 Financial Results and Provides Corporate Update - Recent ODYSSEY Phase 2b Trial of Suprachoroidal CLS-AX in Wet AMD Achieved All Primary and Secondary Outcomes - - Positive Topline Results Support Advancing CLS-AX to Phase 3 Targeting a Differentiated Flexible Dosing Approach Similar to a Biologic with the Potential Extended Duration o

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2024 Clearside Biomedical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37783 45-2437375 (State or Other Jurisdiction of Incorporation) (Commi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37783 Clearside Biomedical, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 09, 2024 Clearside Biomedical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37783 45-2437375 (State or Other Jurisdiction of Incorporation) (Commis

Clearside Biomedical Announces Positive Topline Results from ODYSSEY Phase 2b Trial of Suprachoroidal CLS-AX in Wet AMD Achieving All Primary and Secondary Outcomes - Maintained Stable Visual Acuity and Anatomical Control Over 9 Months - - Positive S

Exhibit 99.2 Clearside Biomedical Announces Positive Topline Results from ODYSSEY Phase 2b Trial of Suprachoroidal CLS-AX in Wet AMD Achieving All Primary and Secondary Outcomes - Maintained Stable Visual Acuity and Anatomical Control Over 9 Months - - Positive Safety Profile with No Ocular or Treatment-Related Serious Adverse Events - - 67% of CLS-AX Participants Did Not Require Any Additional Tr

Forward-Looking Statements This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “int

ODYSSEY Phase 2b Clinical Trial Results October 9, 2024 Exhibit 99.1 Forward-Looking Statements This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “targ

Clearside Biomedical Announces Second Quarter 2024 Financial Results and Provides Corporate Update - Phase 2b ODYSSEY Trial in Wet AMD Remains on Track with Topline Data Expected in Late Q3 2024 - - ODYSSEY Safety Review Committee Recommends Trial Co

Exhibit 99.1 Clearside Biomedical Announces Second Quarter 2024 Financial Results and Provides Corporate Update - Phase 2b ODYSSEY Trial in Wet AMD Remains on Track with Topline Data Expected in Late Q3 2024 - - ODYSSEY Safety Review Committee Recommends Trial Continue as Planned with no Serious Adverse Events Observed - - Recent Key Opinion Leader Webinar Highlighted the Broad Applicability and R

First Amendment to License Agreement, by and among the Registrant and BioCryst Pharmaceuticals, Inc., dated as of May 20, 2024.

Exhibit 10.1 Certain information has been excluded from this agreement (indicated by “[***]”) because such information is both (a) not material and (b) the type that the registrant customarily and actually treats as private or confidential. AMENDMENT 1 TO THE LICENSE AGREEMENT THIS FIRST AMENDMENT to the LICENSE AGREEMENT (the “Amendment”) is made and entered into on this 20th day of May 2024 (the

Employment Agreement, by and between Registrant and Victor Chong, dated as of June 19, 2024.

Exhibit 10.2 EXECUTIVE EMPLOYMENT AGREEMENT THIS EXECUTIVE EMPLOYMENT AGREEMENT (the “Agreement”), is entered into effective as of June 19, 2024, (the “Effective Date”), by and between Clearside Biomedical, Inc., a Delaware corporation (the “Company”), and Victor Chong (the “Executive”), an individual residing in California. W I T N E S S E T H: WHEREAS, the Company and Executive desire to set for

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37783 Clearside Biomedical, Inc.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2024 Clearside Biomedical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37783 45-2437375 (State or Other Jurisdiction of Incorporation) (Commiss

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 24, 2024 Clearside Biomedical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37783 45-2437375 (State or Other Jurisdiction of Incorporation) (Commissio

Forward-Looking Statements This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “int

Suprachoroidal Space Drug Delivery July 24, 2024 Exhibit 99.1 Forward-Looking Statements This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” or

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 20, 2024 Clearside Biomedical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37783 45-2437375 (State or Other Jurisdiction of Incorporation) (Commissio

Filing Fee Table.

Exhibit 107 Calculation of Filing Fee Table Form S-8 CLEARSIDE BIOMEDICAL, INC. (Exact name of Registrant as specified in its charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, par value $0.001 p

Amended and Restated Non-Employee Director Compensation Policy.

Exhibit 10.3 Clearside Biomedical, Inc. Non-Employee Director Compensation Policy As Amended and Restated effective March 14, 2024 Each member of the Board of Directors (the “Board”) who is not also serving as an employee of Clearside Biomedical, Inc. (the “Company”) or any of its subsidiaries (each such member, an “Eligible Director”) will receive the compensation described in this Non-Employee D

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37783 Clearside Biomedical, Inc.

As filed with the Securities and Exchange Commission on May 10, 2024

As filed with the Securities and Exchange Commission on May 10, 2024 Registration No.

Clearside Biomedical Announces First Quarter 2024 Financial Results and Provides Corporate Update - Phase 2b ODYSSEY Trial in Wet AMD Remains on Track with Topline Data Expected Q3 2024 - - Strengthened Management Team and Board of Directors with Two

Exhibit 99.1 Clearside Biomedical Announces First Quarter 2024 Financial Results and Provides Corporate Update - Phase 2b ODYSSEY Trial in Wet AMD Remains on Track with Topline Data Expected Q3 2024 - - Strengthened Management Team and Board of Directors with Two Key Additions - - Management to Host Webcast and Conference Call Today at 4:30 P.M. ET - ALPHARETTA, Ga., May 9, 2024 - Clearside Biomed

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 09, 2024 Clearside Biomedical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37783 45-2437375 (State or Other Jurisdiction of Incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 15, 2024 Clearside Biomedical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37783 45-2437375 (State or Other Jurisdiction of Incorporation) (Commissi

Clearside Biomedical Appoints Seasoned Biotechnology Executive Anthony S. Gibney to its Board of Directors - Appointment Adds Broad Expertise in Business Strategy, Collaborations, Finance, and M&A with Recent Ophthalmic Experience -

Exhibit 99.1 Clearside Biomedical Appoints Seasoned Biotechnology Executive Anthony S. Gibney to its Board of Directors - Appointment Adds Broad Expertise in Business Strategy, Collaborations, Finance, and M&A with Recent Ophthalmic Experience - ALPHARETTA, Ga., April 16, 2024 - Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the

License Agreement, by and between the Registrant and BioCryst Pharmaceuticals, Inc., dated as of November 1, 2023.

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37783 Clearside Biomedical, Inc.

First Amendment to Consulting Agreement, by and between Registrant and Thomas Ciulla, dated as of February 17, 2024.

Exhibit 10.35 FIRST AMENDMENT TO CONSULTING AGREEMENT This First Amendment to Consulting Agreement (the “Amendment”), effective as of February 17, 2024 (the “Amendment Effective Date”) by and among Dr. Thomas Ciulla (“Consultant”), and Clearside Biomedical, Inc (“Client”), amends the Consulting Agreement dated February 17, 2023 (the “Agreement”). Each of Consultant and Client shall be referred to

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 12, 2024 Clearside Biomedical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37783 45-2437375 (State or Other Jurisdiction of Incorporation) (Commissi

Clearside Biomedical, Inc. Clawback Policy.

Exhibit 97 Clearside Biomedical, Inc. Incentive Compensation Recoupment Policy 1. Introduction The Board of Directors (the “Board”) of Clearside Biomedical, Inc., a Delaware corporation (the “Company”), has determined that it is in the best interests of the Company and its stockholders to adopt this Incentive Compensation Recoupment Policy (this “Policy”) providing for the Company’s recoupment of

Fourth Amendment to License Agreement, by and among the Registrant, Emory University and The Georgia Tech Research Corporation, dated January 31, 2024.

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

Clearside Biomedical Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update - Phase 2b ODYSSEY Wet AMD Trial Remains on Track with Topline Data Expected in Q3 2024 - - Partner Programs Continue to Report Positive

Exhibit 99.1 Clearside Biomedical Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update - Phase 2b ODYSSEY Wet AMD Trial Remains on Track with Topline Data Expected in Q3 2024 - - Partner Programs Continue to Report Positive Clinical Data Utilizing SCS Microinjector® - - Strengthened Capital Position from Registered Direct Equity Offering and Recent SCS Microi

Form of Warrant to Purchase Common Stock issued to investors in February 2024 in connection with Securities Purchase Agreement (incorporated herein by reference to Exhibit 4.1 to the Registrant’s Current Report on Form 8-K (File No. 001-37783), filed with the Commission on February 8, 2024).

Exhibit 4.1 COMMON STOCK PURCHASE WARRANT CLEARSIDE BIOMEDICAL, INC. Warrant Shares: Initial Exercise Date: August 9, 2024 Issue Date: February 9, 2024 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 6, 2024 CLEARSIDE BIOMEDICAL, INC. (Exact name of Registrant as specified in its charter) Delaware 001-37783 45-2437375 (State or other jurisdiction of incorporation) (Commis

Clearside Biomedical Announces Pricing of $15 Million Registered Direct Offering

Exhibit 99.1 Clearside Biomedical Announces Pricing of $15 Million Registered Direct Offering ALPHARETTA, Ga., February 7, 2024 — Clearside Biomedical, Inc. (“Clearside” or the “Company”) (NASDAQ: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that it has entered into a securities purchase

Form of Securities Purchase Agreement, dated February 6, 2024 by and among Clearside Biomedical, Inc. and the purchasers party thereto.

Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of February 6, 2024, between Clearside Biomedical, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and condi

11,111,111 Shares of Common Stock Warrants to Purchase 11,111,111 Shares of Common Stock Up to 11,111,111 Shares of Common Stock underlying such Warrants

Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-271902 PROSPECTUS SUPPLEMENT (To Prospectus Dated May 19, 2023) 11,111,111 Shares of Common Stock Warrants to Purchase 11,111,111 Shares of Common Stock Up to 11,111,111 Shares of Common Stock underlying such Warrants We are offering to certain investors 11,111,111 shares of our common stock and warrants to purchase up to 11,1

Placement Agency Agreement, dated February 6, 2024 by and among Clearside Biomedical, Inc. and Citizens JMP Securities, LLC

Exhibit 10.2 PLACEMENT AGENCY AGREEMENT February 6, 2024 Dr. George Lasezkay President and Chief Executive Officer Clearside Biomedical, Inc. 900 North Point Parkway, Suite 200 Alpharetta, Georgia 30005 Dear Dr. Lasezkay: This agreement (the “Agreement”) constitutes the agreement between Citizens JMP Securities, LLC (“Citizens JMP” or the “Placement Agent”) and Clearside Biomedical, Inc., a compan

Entry into a Material Definitive Agreement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 31, 2024 Clearside Biomedical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37783 45-2437375 (State or Other Jurisdiction of Incorporation) (Commis

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 22, 2023 Clearside Biomedical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37783 45-2437375 (State or Other Jurisdiction of Incorporation) (Commi

Letter Agreement, by and among Clearside Royalty LLC, Healthcare Royalty Partners IV, L.P. and HCR Clearside SPV, LLC (as assignee of HCR Collateral Management, LLC), dated as of December 22, 2023 (incorporated herein by reference to Exhibit 10.1 to the (incorporated herein by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K (File No. 001-37783), filed with the Commission on December 28, 2023).

Exhibit 10.1 HCR Clearside SPV, LLC Healthcare Royalty Partners IV, L.P. 300 Atlantic Street, Suite 600 Stamford, CT 06901 December 22, 2023 Clearside Royalty LLC c/o Clearside Biomedical, Inc. 900 North Point Parkway, Suite 200 Alpharetta, GA 30005 Attn: George Lasezkay Re: Purchase and Sale Agreement Gentlemen: Reference is hereby made to (i) that certain Purchase and Sale Agreement, dated as of

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2023 Clearside Biomedical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37783 45-2437375 (State or Other Jurisdiction of Incorporation) (Commi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37783 Clearside Biomedical, Inc.

Clearside Biomedical Announces Third Quarter 2023 Financial Results and Provides Corporate Update - New Licensing Partnership with BioCryst Pharmaceuticals Expands Clearside’s Proprietary Suprachoroidal Injection Platform to Plasma Kallikrein Inhibit

Exhibit 99.1 Clearside Biomedical Announces Third Quarter 2023 Financial Results and Provides Corporate Update - New Licensing Partnership with BioCryst Pharmaceuticals Expands Clearside’s Proprietary Suprachoroidal Injection Platform to Plasma Kallikrein Inhibitor - - BioCryst Collaboration Provides $5 Million Upfront, the Potential for Additional $77.5 Million in Clinical, Regulatory, and Sales

Entry into a Material Definitive Agreement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 01, 2023 Clearside Biomedical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37783 45-2437375 (State or Other Jurisdiction of Incorporation) (Commi

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 27, 2023 Clearside Biomedical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37783 45-2437375 (State or Other Jurisdiction of Incorporation) (Comm

Clearside Biomedical Announces Second Quarter 2023 Financial Results and Provides Corporate Update - Phase 2b ODYSSEY Trial of CLS-AX in Wet AMD Progressing as Planned with Nearly 30 Sites Now Open - - Proprietary Suprachoroidal Injection Platform Fe

Exhibit 99.1 Clearside Biomedical Announces Second Quarter 2023 Financial Results and Provides Corporate Update - Phase 2b ODYSSEY Trial of CLS-AX in Wet AMD Progressing as Planned with Nearly 30 Sites Now Open - - Proprietary Suprachoroidal Injection Platform Featured in Peer-Reviewed Publication and at ARVO, ASRS and OIS Scientific Meetings - - Management to Host Webcast and Conference Call Toda

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2023 Clearside Biomedical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37783 45-2437375 (State or Other Jurisdiction of Incorporation) (Commiss

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37783 Clearside Biomedical, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 22, 2023 Clearside Biomedical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37783 45-2437375 (State or Other Jurisdiction of Incorporation) (Commissio

[Signature page follows]

CORRESP 1 filename1.htm May 17, 2023 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Mail Stop 4546 Washington, D.C. 20549 Attn: Lauren S. Hamill Re: Clearside Biomedical, Inc. Registration Statement on Form S-3 File No. 333-271902 Acceleration Request Requested Date: May 19, 2023 Requested Time: 4:00 P.M. Eastern Time Ladies and Gentlemen: In a

Controlled Equity OfferingSM Sales Agreement, by and between the Registrant and Cantor Fitzgerald & Co., dated as of May 12, 2023 (incorporated herein by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K (File No. 001-37783), filed with the Commission on May 12, 2023).

Exhibit 10.1 CLEARSIDE BIOMEDICAL, INC. Shares of Common Stock (par value $0.001 per share) Controlled Equity OfferingSM Sales Agreement May 12, 2023 Cantor Fitzgerald & Co. 499 Park Avenue New York, NY 10022 Ladies and Gentlemen: Clearside Biomedical, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cantor Fitzgerald & Co. (the “Agent”), as follows: 1.

Form of Indenture, between the Registrant and one or more trustees to be named.

EX-4.3 Exhibit 4.3 CLEARSIDE BIOMEDICAL, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [•], 20 Debt Securities TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trustee’s Certifi

Form of Preferred Stock Warrant Agreement and Warrant Certificate.

EX-4.6 Exhibit 4.6 CLEARSIDE BIOMEDICAL, INC. AND , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF CLEARSIDE BIOMEDICAL, INC. FORM OF PREFERRED STOCK WARRANT AGREEMENT THIS PREFERRED STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [•], between CLEARSIDE BIOMEDICAL, INC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association]

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Clearside Biomedical, Inc.

Form of Debt Securities Warrant Agreement and Warrant Certificate.

EX-4.7 Exhibit 4.7 CLEARSIDE BIOMEDICAL, INC. AND , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF CLEARSIDE BIOMEDICAL, INC. FORM OF DEBT SECURITIES WARRANT AGREEMENT THIS DEBT SECURITIES WARRANT AGREEMENT (this “Agreement”), dated as of [•], between CLEARSIDE BIOMEDICAL, INC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association]

As filed with the Securities and Exchange Commission on May 12, 2023

As filed with the Securities and Exchange Commission on May 12, 2023 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2023 Clearside Biomedical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37783 45-2437375 (State or Other Jurisdiction of Incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37783 Clearside Biomedical, Inc.

Form of Common Stock Warrant Agreement and Warrant Certificate.

EX-4.5 Exhibit 4.5 CLEARSIDE BIOMEDICAL, INC. AND , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF CLEARSIDE BIOMEDICAL, INC. FORM OF COMMON STOCK WARRANT AGREEMENT THIS COMMON STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [●], between CLEARSIDE BIOMEDICAL, INC., a Delaware corporation (the “Company”), and [●], a [corporation] [national banking association] organized

As filed with the Securities and Exchange Commission on May 12, 2023

Form S-3 Table of Contents As filed with the Securities and Exchange Commission on May 12, 2023 Registration No.

Filing Fee Table.

Exhibit 107 Calculation of Filing Fee Table Form S-8 CLEARSIDE BIOMEDICAL, INC. (Exact name of Registrant as specified in its charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, par value $0.001 pe

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2023 Clearside Biomedical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37783 45-2437375 (State or Other Jurisdiction of Incorporation) (Commission

Clearside Biomedical Announces First Quarter 2023 Financial Results and Provides Corporate Update - Phase 2b ODYSSEY Trial of CLS-AX in Wet AMD Expected to Open Enrollment in Q2 2023 - - Positive Safety Data, Duration and Biologic Effect of CLS-AX Ov

Exhibit 99.1 Clearside Biomedical Announces First Quarter 2023 Financial Results and Provides Corporate Update - Phase 2b ODYSSEY Trial of CLS-AX in Wet AMD Expected to Open Enrollment in Q2 2023 - - Positive Safety Data, Duration and Biologic Effect of CLS-AX Over 6 Months in OASIS Phase 1/2a Extension Study Highlighted in Presentations at Recent Medical Meetings - - Management to Host Webcast an

Proxy Statement

DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Pro

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 18, 2023 Clearside Biomedical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37783 45-2437375 (State or Other Jurisdiction of Incorporation) (Commissi

Form 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37783 Clearside Biomedical, Inc.

First Amendment to Office Lease Agreement, by and between the Registrant and Radiant-North Point Properties, LLLP, dated as of November 1, 2022 (incorporated herein by reference to Exhibit 10.29 to the Registrant’s Annual Report on Form 10-K (File No. 001-37783), filed with the Commission on March 14, 2023).

Exhibit 10.29 FIRST AMENDMENT TO OFFICE LEASE AGREEMENT THIS FIRST AMENDMENT TO OFFICE LEASE AGREEMENT (this "First Amendment") is made and entered into effective as of the 1st day of November, 2022, by and between RADIANT-NORTH POINT PROPERTIES, LLLP, a Delaware limited liability limited partnership (as "Landlord"), and CLEARSIDE BIOMEDICAL, INC., a Delaware corporation (as "Tenant"). WITNESSETH:

First Amendment to Option and License Agreement, by and between the Registrant and REGENXBIO, Inc., dated as of January 14, 2023 (incorporated herein by reference to Exhibit 10.30 to the Registrant’s Annual Report on Form 10-K (File No. 001-37783), filed with the Commission on March 14, 2023).

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

Clearside Biomedical Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update - Initiation of Phase 2b ODYSSEY Trial of CLS-AX in Wet AMD Expected in Q2 2023 - - Medical Meeting Presentations Highlight Significant P

Exhibit 99.1 Clearside Biomedical Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update - Initiation of Phase 2b ODYSSEY Trial of CLS-AX in Wet AMD Expected in Q2 2023 - - Medical Meeting Presentations Highlight Significant Potential of CLS-AX Based on Positive OASIS Phase 1/2a Safety Data, Durability, and Biologic Effect Over 6 Months - - Continued Growth in

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 09, 2023 Clearside Biomedical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37783 45-2437375 (State or Other Jurisdiction of Incorporation) (Commissi

Consulting Agreement, by and between Clearside Biomedical, Inc. and Dr. Thomas Ciulla, dated as of February 17, 2023.

Exhibit 10.1 CLEARSIDE BIOMEDICAL, INC. CONSULTING AGREEMENT Effective Date: February 17, 2023 This Consulting Agreement (the “Agreement”) is made as of the Effective Date set forth above by and between Clearside Biomedical, Inc. (“Client”) and Dr. Thomas Ciulla (“Consultant”). RECITALS WHEREAS, Consultant was employed by Client as its Chief Medical Officer and Chief Development Officer pursuant t

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 17, 2023 Clearside Biomedical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37783 45-2437375 (State or Other Jurisdiction of Incorporation) (Commi

CLSD / Clearside Biomedical Inc / RTW INVESTMENTS, LP - CLEARSIDE BIOMEDICAL, INC. Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 4)* Clearside Biomedical, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 185063104 (CUSIP Number) December 31, 2022 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pur

CLSD / Clearside Biomedical Inc / Carmignac Gestion - AMENDMENT NO. 2 TO SCHEDULE 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Clearside Biomedical, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 185063104 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 02, 2023 Clearside Biomedical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37783 45-2437375 (State or Other Jurisdiction of Incorporation) (Commi

Clearside Biomedical Announces Positive 6-Month Results from OASIS Extension Study with Suprachoroidal CLS-AX (axitinib injectable suspension) in Wet AMD - Suprachoroidal CLS-AX Resulted in Favorable Safety Data, Durability and Biologic Effect Over 6

Exhibit 99.2 Clearside Biomedical Announces Positive 6-Month Results from OASIS Extension Study with Suprachoroidal CLS-AX (axitinib injectable suspension) in Wet AMD - Suprachoroidal CLS-AX Resulted in Favorable Safety Data, Durability and Biologic Effect Over 6 Months in Treatment-Experienced Anti-VEGF Sub-Responders - - 67% of Extension Study Participants Went at Least 6 Months Without Needing

Forward-Looking Statements This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “int

TM OASIS Phase 1/2a Clinical Trial 6-Month Extension Study Results February 2, 2023 Exhibit 99.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 2, 2023 Clearside Biomedic

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 2, 2023 Clearside Biomedical, Inc.

CLSD / Clearside Biomedical Inc / Hatteras Venture Advisors III, LLC - SC 13D/A Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 6)* Under the Securities Exchange Act of 1934 CLEARSIDE BIOMEDICAL, INC. (Name of Issuer) Common Stock, $0.001 Par Value (Title of Class of Securities) 185063 10 4 (CUSIP Number) Clay Thorp 280 S. Mangum Street, Suite 350 Durham, North Carolina 27701 (919) 484-0730 (Name, Address and Telephone Numbe

Clearside Biomedical Announces Third Quarter 2022 Financial Results and Provides Corporate Update - Favorable Safety Results, Durability and Biologic Effect Observed in Cohorts 3 and 4 of CLS-AX OASIS Phase 1/2a Trial - - Recent Positive Data Present

Exhibit 99.1 Clearside Biomedical Announces Third Quarter 2022 Financial Results and Provides Corporate Update - Favorable Safety Results, Durability and Biologic Effect Observed in Cohorts 3 and 4 of CLS-AX OASIS Phase 1/2a Trial - - Recent Positive Data Presentations Highlight the Potential Safety, Efficacy and Durability Benefits of Suprachoroidal Administration of Small Molecule Suspensions -

Clearside Biomedical Announces Positive Results in Safety, Durability and Biologic Effect in OASIS Phase 1/2a Clinical Trial of Suprachoroidal CLS-AX (axitinib injectable suspension) in Wet AMD Patients - Primary Safety Endpoint Achieved at all Timep

Exhibit 99.2 Clearside Biomedical Announces Positive Results in Safety, Durability and Biologic Effect in OASIS Phase 1/2a Clinical Trial of Suprachoroidal CLS-AX (axitinib injectable suspension) in Wet AMD Patients - Primary Safety Endpoint Achieved at all Timepoints with All Doses Well-Tolerated and No Treatment Related or Serious Adverse Events - - Cohorts 3 and 4 Demonstrated Promising Signs o

Purchase and Sale Agreement, by and among Clearside Royalty LLC, Healthcare Royalty Partners IV, L.P. and HCR Collateral Management, LLC (in its capacity as agent for Purchaser), dated as of August 8, 2022 (incorporated herein by reference to Exhibit 10.1 to the Registrant's Quarterly Report on Form 10-Q (File No. 001-37783), filed with the Commission on November 9, 2022).

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

Forward-Looking Statements This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “int

OASIS Phase 1/2a Clinical Trial Results November 9, 2022 TM Exhibit 99.3 Forward-Looking Statements This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. The words ?may,? ?will,? ?could,? ?would,? ?should,? ?expect,? ?plan,? ?anticipate,? ?intend,? ?believe,? ?estimate,? ?predict,? ?project,? ?potential,? ?continue,? ?

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37783 Clearside Biomedical, Inc.

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 09, 2022 Clearside Biomedical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37783 45-2437375 (State or Other Jurisdiction of Incorporation) (Commi

Fourth Amended and Restated Non-Employee Director Compensation Policy (incorporated by reference to Exhibit 10.1 to the Registrant's Quarterly Report on Form 10-Q (File No. 001-37783) filed with the Commission on August 12, 2022).

Exhibit 10.1 Clearside Biomedical, Inc. Non-Employee Director Compensation Policy As Amended and Restated effective June 22, 2022 Each member of the Board of Directors (the ?Board?) who is not also serving as an employee of Clearside Biomedical, Inc. (the ?Company?) or any of its subsidiaries (each such member, an ?Eligible Director?) will receive the compensation described in this Non-Employee Di

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37783 Clearside Biomedical, Inc.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 09, 2022 Clearside Biomedical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37783 45-2437375 (State or Other Jurisdiction of Incorporation) (Commiss

Clearside Biomedical Announces Second Quarter 2022 Financial Results and Provides Corporate Update - CLS-AX OASIS Phase 1/2a Trial Data from Cohorts 3 & 4 Expected in November 2022 - - Non-Dilutive Financing Agreement with HealthCare Royalty Supports

Exhibit 99.1 Clearside Biomedical Announces Second Quarter 2022 Financial Results and Provides Corporate Update - CLS-AX OASIS Phase 1/2a Trial Data from Cohorts 3 & 4 Expected in November 2022 - - Non-Dilutive Financing Agreement with HealthCare Royalty Supports Progression of CLS-AX Clinical Program - - Management to Host Webcast and Conference Call Today at 8:30 A.M. ET - ALPHARETTA, Ga., Augus

Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 08, 2022 Clearside Biomedical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37783 45-2437375 (State or Other Jurisdiction of Incorporation) (Commiss

Clearside Biomedical Enters into Non-Dilutive Financing Agreement with HealthCare Royalty Partners for up to $65 Million - Transaction Supports Progression of CLS-AX Clinical Program -

Exhibit 99.1 Clearside Biomedical Enters into Non-Dilutive Financing Agreement with HealthCare Royalty Partners for up to $65 Million - Transaction Supports Progression of CLS-AX Clinical Program - ALPHARETTA, Ga., August August 8, 2022 - Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroida

Certificate of Amendment to Amended and Restated Certificate of Incorporation (incorporated herein by reference to Exhibit 3.1 to the Registrant's Current Report on Form 8-K (File No. 001-37783) filed with the SEC on June 23, 2022).

Exhibit 3.1 CERTIFICATE OF AMENDMENT TO AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF CLEARSIDE BIOMEDICAL, INC. Clearside Biomedical, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the ?DGCL?), certifies: FIRST: The name of the corporation is Clearside Biomedical, Inc. (the ?Company?). SECOND: The Company?s original C

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 22, 2022 Clearside Biomedical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37783 45-2437375 (State or Other Jurisdiction of Incorporation) (Commissio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37783 Clearside Biomedical, Inc.

As filed with the Securities and Exchange Commission on May 12, 2022

As filed with the Securities and Exchange Commission on May 12, 2022 Registration No.

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Table Form S-8 CLEARSIDE BIOMEDICAL, INC. (Exact name of Registrant as specified in its charter) CALCULATION OF REGISTRATION FEE Title of Securities to be Registered Amount to be Registered (1) Proposed Maximum Offering Price Per Share(2) Proposed Maximum Aggregate Offering Price(2) Fee Rate Amount of Registration Fee Common Stock, par value $0.001 per share 2

Clearside Biomedical Announces First Quarter 2022 Financial Results and Provides Corporate Update - First Approved Suprachoroidal Product, XIPERE®, Now Commercially Available in U.S. - - Cohort 4 Enrolling at 1.0 mg Dose in CLS-AX OASIS Wet AMD Phase

Exhibit 99.1 Clearside Biomedical Announces First Quarter 2022 Financial Results and Provides Corporate Update - First Approved Suprachoroidal Product, XIPERE?, Now Commercially Available in U.S. - - Cohort 4 Enrolling at 1.0 mg Dose in CLS-AX OASIS Wet AMD Phase 1/2a Trial - - Management to Host Webcast and Conference Call Today at 4:30 P.M. ET - ALPHARETTA, Ga., May 11, 2022 - Clearside Biomedic

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2022 Clearside Biomedical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37783 45-2437375 (State or Other Jurisdiction of Incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37783 Clearside Biomedical, Inc.

Third Amended and Restated Non-Employee Director Compensation Policy.

Exhibit 10.14 Clearside Biomedical, Inc. Non-Employee Director Compensation Policy As Amended and Restated effective June 18, 2020 Each member of the Board of Directors (the ?Board?) who is not also serving as an employee of Clearside Biomedical, Inc. (the ?Company?) or any of its subsidiaries (each such member, an ?Eligible Director?) will receive the compensation described in this Non-Employee D

Clearside Biomedical Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update - XIPERE® -Related Milestones Generated $20 Million in Non-Dilutive Funding in Q4 2021 - - Continued Progress in CLS-AX OASIS Wet AMD Pha

Exhibit 99.1 Clearside Biomedical Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update - XIPERE? -Related Milestones Generated $20 Million in Non-Dilutive Funding in Q4 2021 - - Continued Progress in CLS-AX OASIS Wet AMD Phase 1/2a Trial with Cohort 3 Results Expected Mid-2022 - - New Cohort 4 Planned in Q2 2022 to Expand CLS-AX Dose Escalation in OASIS Trial

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2022 Clearside Biomedical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37783 45-2437375 (State or Other Jurisdiction of Incorporation) (Commissi

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 03, 2022 Clearside Biomedical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37783 45-2437375 (State or Other Jurisdiction of Incorporation) (Commissi

Clearside Biomedical Appoints Benjamin R. Yerxa, Ph.D. to its Board of Directors - Industry Veteran Brings Broad Ophthalmology Research & Development Expertise -

Exhibit 99.1 Clearside Biomedical Appoints Benjamin R. Yerxa, Ph.D. to its Board of Directors - Industry Veteran Brings Broad Ophthalmology Research & Development Expertise - ALPHARETTA, Ga., March 3, 2022 - Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS?), announced today

CLSD / Clearside Biomedical Inc / RTW INVESTMENTS, LP - CLEARSIDE BIOMEDICAL, INC. Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* Clearside Biomedical, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 185063104 (CUSIP Number) December 31, 2021 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pur

CLSD / Clearside Biomedical Inc / Carmignac Gestion - AMENDMENT NO. 1 TO SCHEDULE 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Clearside Biomedical, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 185063104 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate

Forward-Looking Statements This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “int

OASIS Phase 1/2a Clinical Trial Safety Results December 21, 2021 Exhibit 99.1 Forward-Looking Statements This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. The words ?may,? ?will,? ?could,? ?would,? ?should,? ?expect,? ?plan,? ?anticipate,? ?intend,? ?believe,? ?estimate,? ?predict,? ?project,? ?potential,? ?continu

Regulation FD Disclosure, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 21, 2021 Clearside Biomedical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37783 45-2437375 (State or Other Jurisdiction of Incorporation) (Commi

Clearside Biomedical Announces Positive Safety Results from OASIS Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) for the Treatment of Wet AMD - Suprachoroidal Injection of CLS-AX 0.1 mg Dose Well-Tolerated in Cohort 2 with No Tr

Exhibit 99.2 Clearside Biomedical Announces Positive Safety Results from OASIS Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) for the Treatment of Wet AMD - Suprachoroidal Injection of CLS-AX 0.1 mg Dose Well-Tolerated in Cohort 2 with No Treatment Related Adverse Events ? - Consistent Safety Profile Observed in Cohorts 1 and 2 Supports Advancement to Cohort 3 - - Webcast and

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37783 Clearside Biomedical, Inc.

Clearside Biomedical Announces Third Quarter 2021 Financial Results and Provides Corporate Update - XIPERE™ is First FDA-Approved Product for Injection into the Suprachoroidal Space - - Approval-Related Milestones to Provide $19 Million in Non-Diluti

Exhibit 99.1 Clearside Biomedical Announces Third Quarter 2021 Financial Results and Provides Corporate Update - XIPERE? is First FDA-Approved Product for Injection into the Suprachoroidal Space - - Approval-Related Milestones to Provide $19 Million in Non-Dilutive Funding - - Continued Progress in CLS-AX Wet AMD Phase 1/2a Trial - - Management to Host Webcast and Conference Call Today at 4:30 P.M

Second Amendment to the License Agreement, by and between the Registrant and Arctic Vision (Hong Kong) Limited, dated as of September 9, 2021 (incorporated herein by reference to Exhibit 10.2 to the Registrant's Quarterly Report on Form 10-Q (File No. 001-37783), filed with the Commission on November 10, 2021.

Exhibit 10.2 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. Amendment No. 2 to License Agreement This Amendment No. 2 to License Agreement (the ?Amendment?) is effective as of September 9th, 2021 (the ?Amendment Effective Date?) by and betw

First Amendment to the License Agreement, by and between the Registrant and Arctic Vision (Hong Kong) Limited, dated as of August 15, 2021 (incorporated herein by reference to Exhibit 10.1 to the Registrant's Quarterly Report on Form-10 (File No. 001-37783), filed with the Commission on November 10, 2021.

Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. Amendment No. 1 to License Agreement This Amendment No. 1 to License Agreement (the ?Amendment?) is effective as of August 15th, 2021 (the ?Amendment Effective Date?) by and betwee

Second Amendment to the License Agreement, by and between the Registrant and Bausch + Lomb Ireland Limited (as assignee of Bausch Health Ireland Limited), dated as of September 27, 2021 (incorporated herein by reference to Exhibit 10.3 to the Registrant's Quarterly Report on Form 10-Q (File No. 001-37783), filed with the Commission on November 10, 2021.

Exhibit 10.3 SECOND AMENDMENT TO LICENSE AGREEMENT This Second Amendment to License Agreement (the ?Second Amendment?), effective as of September 27, 2021 (the ?Second Amendment Effective Date?) by and between Bausch + Lomb Ireland Limited (as assignee of Bausch Health Ireland Limited) (?Bausch?) and Clearside Biomedical, Inc. (?Clearside?), amends that certain License Agreement, dated October 22,

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2021 Clearside Biomedical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37783 45-2437375 (State or Other Jurisdiction of Incorporation) (Commi

Regulation FD Disclosure, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 25, 2021 Clearside Biomedical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37783 45-2437375 (State or Other Jurisdiction of Incorporation) (Commis

BAUSCH + LOMB AND CLEARSIDE BIOMEDICAL ANNOUNCE FDA APPROVAL OF XIPERE™ (TRIAMCINOLONE ACETONIDE INJECTABLE SUSPENSION) FOR SUPRACHOROIDAL USE FOR THE TREATMENT OF MACULAR EDEMA ASSOCIATED WITH UVEITIS XIPERE™ is the First and Only Medicine to be App

Exhibit 99.1 Clearside Investor and Media Contacts: Jenny Kobin Remy Bernarda [email protected] (678) 430-8206 Bausch Health Investor Contact: Arthur Shannon [email protected] (514) 865-3855 (877) 281-6642 (toll free) Bausch Health Media Contact: Lainie Keller [email protected] (908) 927-1198 BAUSCH + LOMB AND CLEARSIDE BIOMEDICAL ANNOUNCE FDA APPROVAL OF XIPERE? (TRIA

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37783 Clearside Biomedical, Inc.

Clearside Biomedical Announces Second Quarter 2021 Financial Results and Provides Corporate Update - Enrollment Underway in Cohort 2 of OASIS Wet AMD Phase 1/2a Trial with Data Expected by the End of 2021 – - Upcoming FDA PDUFA Action Date in October

Exhibit 99.1 Clearside Biomedical Announces Second Quarter 2021 Financial Results and Provides Corporate Update - Enrollment Underway in Cohort 2 of OASIS Wet AMD Phase 1/2a Trial with Data Expected by the End of 2021 ? - Upcoming FDA PDUFA Action Date in October 2021 for XIPERETM (triamcinolone acetonide suprachoroidal injectable suspension) - - Management to Host Webcast and Conference Call Toda

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2021 Clearside Biomedical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37783 45-2437375 (State or Other Jurisdiction of Incorporation) (Commiss

Clearside Biomedical Announces Positive Safety Results from Cohort 1 of OASIS Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) for the Treatment of Wet AMD - CLS-AX 0.03 mg dose delivered via suprachoroidal injection was well-tole

Exhibit 99.2 Clearside Biomedical Announces Positive Safety Results from Cohort 1 of OASIS Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) for the Treatment of Wet AMD - CLS-AX 0.03 mg dose delivered via suprachoroidal injection was well-tolerated with no treatment related adverse events - - Initiating Cohort 2 patient screening for 0.1 mg dose in June 2021- ALPHARETTA, Ga., J

Regulation FD Disclosure, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2021 Clearside Biomedical, Inc.

Forward-Looking Statements This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “int

Corporate Presentation | June 2021 Exhibit 99.1 Forward-Looking Statements This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. The words ?may,? ?will,? ?could,? ?would,? ?should,? ?expect,? ?plan,? ?anticipate,? ?intend,? ?believe,? ?estimate,? ?predict,? ?project,? ?potential,? ?continue,? ?target? and similar expre

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2021 Clearside Biomedical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37783 45-2437375 (State or Other Jurisdiction of Incorporation) (Commissio

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 02, 2021 Clearside Biomedical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37783 45-2437375 (State or Other Jurisdiction of Incorporation) (Commissio

Clearside Biomedical Announces First Quarter 2021 Financial Results and Provides Corporate Update - Recent New Drug Application Resubmission for XIPERETM (triamcinolone acetonide suprachoroidal injectable suspension) - - Cohort 1 Data in OASIS Wet AM

EXHIBIT 99.1 Clearside Biomedical Announces First Quarter 2021 Financial Results and Provides Corporate Update - Recent New Drug Application Resubmission for XIPERETM (triamcinolone acetonide suprachoroidal injectable suspension) - - Cohort 1 Data in OASIS Wet AMD Phase 1/2a Trial Expected in June 2021 - - Multiple ARVO Presentations Highlight Suprachoroidal Delivery with SCS Microinjector? - - Ma

As filed with the Securities and Exchange Commission on May 17, 2021

As filed with the Securities and Exchange Commission on May 17, 2021 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37783 Clearside Biomedical, Inc.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 17, 2021 Clearside Biomedical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37783 45-2437375 (State or Other Jurisdiction of Incorporation) (Commission

- DEF 14A

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e

- DEFA14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive

Annual Report - 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37783 Clearside Biomedical, Inc.

Resolutions adopted by the Board of Directors of the Registrant setting forth the information with respect to the Ratification required under Section 204 of the Delaware General Corporation Law.

Exhibit 99.1 Action by Written Consent of the Board of Directors of Clearside Biomedical, Inc. December 10, 2020 The undersigned, being all of the members of the Board of Directors (the ?Board?) of Clearside Biomedical, Inc., a Delaware corporation (the ?Company?), hereby take the following actions by written consent without a meeting pursuant to Sections 141(f) and 204 of the General Corporation

Clearside Biomedical Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update - OASIS Wet AMD Phase 1/2a Trial Initiated and Cohort 1 Dosing Completed - - Initial Safety Data from OASIS Trial Expected Mid-2021 - - F

Exhibit 99.1 Clearside Biomedical Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update - OASIS Wet AMD Phase 1/2a Trial Initiated and Cohort 1 Dosing Completed - - Initial Safety Data from OASIS Trial Expected Mid-2021 - - Four Ongoing Internal & Partner Clinical Trials Using Clearside?s SCS Microinjector? - - Management to Host Webcast and Conference Call To

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8?K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2021 Clearside Biomedical, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Clearside Biomedical, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) (CUSIP Number) Dec

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )*

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Clearside Biomedical, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 185063104 (CUSIP Number) December 31, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate t

Joint Filing Statement Pursuant to Rule 13d-1(k)(1)

Exhibit 1 Joint Filing Statement Pursuant to Rule 13d-1(k)(1) The undersigned hereby consent and agree to the joint filing of Schedule 13G Amendment No.

PLACEMENT AGENCY AGREEMENT

Exhibit 99.2 PLACEMENT AGENCY AGREEMENT January 6, 2021 Roth Capital Partners, LLC 888 San Clemente Drive, Suite 400 Newport Beach, CA 92660 Ladies and Gentlemen: Introduction. Subject to the terms and conditions herein (this “Agreement”), Clearside Biomedical, Inc., a Delaware corporation (the “Company”), hereby agrees to sell up to an aggregate of $12,000,002 of registered shares (the “Shares”)

SECURITIES PURCHASE AGREEMENT

Exhibit 99.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of January 6, 2021, between Clearside Biomedical, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and condit

Clearside Biomedical Announces Pricing of $12 Million Registered Direct Offering

Exhibit 99.3 Clearside Biomedical Announces Pricing of $12 Million Registered Direct Offering ALPHARETTA, Ga., January 6, 2021- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that it has entered into a securities purchase agreem

Financial Statements and Exhibits, Other Events - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8‑K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 6, 2021 Clearside Biomedical, Inc.

4,209,050 Shares Common Stock

Form 424(b)(5) Table of Contents Filed pursuant to Rule 424(b)(5) Registration No.

Other Events - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8‑K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 5, 2021 Clearside Biomedical, Inc.

Clearside Biomedical Announces Third Quarter 2020 Financial Results and Provides Corporate Update - Initiation of Phase 1/2a Trial of CLS-AX (axitinib injectable suspension) for Wet Age-Related Macular Degeneration Expected by Year-End 2020 - - Phase

Exhibit 99.1 Clearside Biomedical Announces Third Quarter 2020 Financial Results and Provides Corporate Update - Initiation of Phase 1/2a Trial of CLS-AX (axitinib injectable suspension) for Wet Age-Related Macular Degeneration Expected by Year-End 2020 - - Phase 2 Trials Using SCS Microinjector® Ongoing by Gene Therapy and Oncology Partners - - Management to Host Webcast and Conference Call Today

Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8‑K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2020 Clearside Biomedical, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37783 Clearside Biomedical, Inc.

First Amendment to License Agreement, by and between the Registrant and Bausch Health Ireland Limited, dated as of April 27, 2020. (incorporated herein by reference to Exhibit 10.1 to the Registrant’s Quarterly Report on Form 10-Q (File No. 001-37783), filed with the Commission on August 10, 2020).

Exhibit 10.1 FIRST AMENDMENT TO LICENSE AGREEMENT This First Amendment to License Agreement (the “Amendment”), effective as of April 27, 2020 (the “Amendment Effective Date”) by and between Bausch Health Ireland Limited (“Bausch Health”) and Clearside Biomedical, Inc. (“Clearside”), amends that certain License Agreement, dated October 22, 2019, by and between Bausch Health and Clearside (the “Agre

Clearside Biomedical Announces Second Quarter 2020 Financial Results and Provides Corporate Update - IND Accepted by FDA for Suprachoroidal CLS-AX (axitinib injectable suspension) - - Expanded Internal Suprachoroidal Pipeline with Two New Preclinical

Exhibit 99.1 Clearside Biomedical Announces Second Quarter 2020 Financial Results and Provides Corporate Update - IND Accepted by FDA for Suprachoroidal CLS-AX (axitinib injectable suspension) - - Expanded Internal Suprachoroidal Pipeline with Two New Preclinical Programs - - Engaged New Contract Manufacturer for XIPERE™ - - Management to Host Webcast and Conference Call Today at 4:30 P.M. ET - AL

Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37783 Clearside Biomedical, Inc.

Executive Employment Agreement, by and between the Registrant and Thomas Ciulla, dated as of June 24, 2019 (incorporated herein by reference to Exhibit 10.2 to the Registrant’s Quarterly Report on Form 10-Q (File No. 001-37783), filed with the Commission on August 10, 2020).

Exhibit 10.2 EXECUTIVE EMPLOYMENT AGREEMENT THIS EXECUTIVE EMPLOYMENT AGREEMENT (the “Agreement”), is entered into effective as of June 24, 2019, (the “Effective Date”), by and between Clearside Biomedical, Inc., a Delaware corporation (the “Company”), and Thomas Ciulla (the “Executive”), an individual residing in Indiana. W I T N E S S E T H: WHEREAS, the Company and Executive desire to set forth

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8‑K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2020 Clearside Biomedical, Inc.

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8‑K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 18, 2020 Clearside Biomedical, Inc.

$50,000,000 Common Stock

Form 424(b)(5) Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No.

-

CORRESP May 20, 2020 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Mail Stop 4546 Washington, D.C. 20549 Attn: Alan Campbell Celeste Murphy Re: Clearside Biomedical, Inc. Registration Statement on Form S-3 File No. 333-238128 Acceleration Request Requested Date: May 22, 2020 Requested Time: 4:00 P.M. Eastern Time Ladies and Gentlemen: In accor

- S-3/A

S-3/A Table of Contents As filed with the Securities and Exchange Commission on May 18, 2020 Registration No.

-

CORRESP Brent Siler +1 202 728 7040 [email protected] VIA EDGAR May 18, 2020 U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attn: Mr. Alan Campbell Ms. Celeste Murphy Re: Clearside Biomedical, Inc. Registration Statement on Form S-3 Filed May 8, 2020 File No. 333-238128 Ladies and Gentlemen: On behalf of our

- S-8

As filed with the Securities and Exchange Commission on May 8, 2020 Registration No.

Form of Common Stock Warrant Agreement and Warrant Certificate.

EX-4.6 Exhibit 4.6 CLEARSIDE BIOMEDICAL, INC. AND , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF CLEARSIDE BIOMEDICAL, INC. FORM OF COMMON STOCK WARRANT AGREEMENT THIS COMMON STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [●], between CLEARSIDE BIOMEDICAL, INC., a Delaware corporation (the “Company”), and [●], a [corporation] [national banking association] organized

Form 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37783 Clearside Biomedical, Inc.

Consent and Fifth Amendment to Second Amended and Restated Loan and Security Agreement, by and between the Registrant and Silicon Valley Bank, dated as of March 11, 2020.

Exhibit 10.1 CONSENT AND FIFTH AMENDMENT TO SECOND AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT This CONSENT AND FIFTH AMENDMENT to Second Amended and Restated Loan and Security Agreement (this “Amendment”) is entered into as of March 11, 2020, by and among SILICON VALLEY BANK, a California corporation (“Bank”), as collateral agent (in such capacity, “Collateral Agent”), Bank in its capacity a

Form of Indenture, between the Registrant and one or more trustees to be named.

EX-4.4 Exhibit 4.4 CLEARSIDE BIOMEDICAL, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [●], 20 Debt Securities TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee’s Certifi

License Agreement by and between the Registrant and Arctic Vision (Hong Kong) Limited, dated as of March 20, 2020 (incorporated herein by reference to Exhibit 10.2 to the Registrant’s Quarterly Report on Form 10-Q (File No. 001-37783), filed with the Commission on May 8, 2020).

Exhibit 10.2 LICENSE AGREEMENT BY AND BETWEEN CLEARSIDE BIOMEDICAL, INC. AND ARCTIC VISION (HONG KONG) LIMITED Certain information has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. TABLE OF CONTENTS Page Article I. DEFINITIONS 1 Article II. LICENSES 12 Article III. GOVERNANCE 16 A

- S-3

S-3 Table of Contents As filed with the Securities and Exchange Commission on May 8, 2020 Registration No.

Form of Preferred Stock Warrant Agreement and Warrant Certificate.

EX-4.7 Exhibit 4.7 CLEARSIDE BIOMEDICAL, INC. AND , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF CLEARSIDE BIOMEDICAL, INC. FORM OF PREFERRED STOCK WARRANT AGREEMENT THIS PREFERRED STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [●], between CLEARSIDE BIOMEDICAL, INC., a Delaware corporation (the “Company”), and [●], a [corporation] [national banking association]

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8‑K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2020 Clearside Biomedical, Inc.

Form of Debt Securities Warrant Agreement and Warrant Certificate.

EX-4.8 Exhibit 4.8 CLEARSIDE BIOMEDICAL, INC. AND , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF CLEARSIDE BIOMEDICAL, INC. FORM OF DEBT SECURITIES WARRANT AGREEMENT THIS DEBT SECURITIES WARRANT AGREEMENT (this “Agreement”), dated as of [●], between CLEARSIDE BIOMEDICAL, INC., a Delaware corporation (the “Company”), and [●], a [corporation] [national banking association]

Clearside Biomedical Announces First Quarter 2020 Financial Results

Exhibit 99.1 Clearside Biomedical Announces First Quarter 2020 Financial Results ALPHARETTA, Ga., May 8, 2020 - Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, today reported financial results for the first quarter ended March 31, 2020. “Our tea

Proxy Statement

DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

- DEFA14A

DEFA14A 1 d886947ddefa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permi

Clearside Biomedical Revises NDA Resubmission Timeline and XIPERE™ Commercial Partnership with Bausch Health - Management to Host Webcast and Conference Call Today at 8:30 A.M. ET -

Exhibit 99.1 Clearside Biomedical Revises NDA Resubmission Timeline and XIPERE™ Commercial Partnership with Bausch Health - Management to Host Webcast and Conference Call Today at 8:30 A.M. ET - ALPHARETTA, Ga., April 28, 2020 - Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with se

Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8‑K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 27, 2020 Clearside Biomedical, Inc.

Clearside Biomedical Appoints Nancy J. Hutson, Ph.D. to its Board of Directors - Pfizer veteran brings global R&D expertise to Board of Directors -

Exhibit 99.1 Clearside Biomedical Appoints Nancy J. Hutson, Ph.D. to its Board of Directors - Pfizer veteran brings global R&D expertise to Board of Directors - ALPHARETTA, Ga., April 22, 2020 - Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, an

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8‑K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 21, 2020 Clearside Biomedical, Inc.

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8‑K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 8, 2020 Clearside Biomedical, Inc.

Forward-Looking Statements This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “int

Corporate Presentation | April 2020 Exhibit 99.1 Forward-Looking Statements This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expr

Amended and Restated Executive Employment Agreement, dated March 11, 2020, by and between the Company and George Lasezkay.

Exhibit 10.1 AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT THIS AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT (the “Agreement”), is entered into effective as of March 11, 2020, (the “Effective Date”), by and between Clearside Biomedical, Inc., a Delaware corporation (the “Company”), and George Lasezkay (the “Executive”), an individual residing in Tennessee. W I T N E S S E T H: WHEREAS

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8‑K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 11, 2020 Clearside Biomedical, Inc.

Option and License Agreement by and between the Registrant and REGENXBIO Inc., dated as of August 29, 2019 (incorporated herein by reference to Exhibit 10.30 to the Registrant’s Annual Report on Form 10-K (File No. 001-37783), filed with the Commission on March 13, 2020).

Exhibit 10.30 OPTION AND LICENSE AGREEMENT BY AND BETWEEN REGENXBIO INC. AND CLEARSIDE BIOMEDICAL, INC. August 29, 2019 Certain information has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. TABLE OF CONTENTS 1. DEFINITIONS1 2. OPTION12 2.1. Option12 2.2. Exercise of Option12 2.3.

Consent and Fourth Amendment to Second Amended and Restated Loan and Security Agreement, by and between the Registrant and Silicon Valley Bank, dated as of October 22, 2019.

Exhibit 10.24 CONSENT AND FOURTH AMENDMENT TO SECOND AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT THIS CONSENT AND FOURTH AMENDMENT to Second Amended and Restated Loan and Security Agreement (this “Amendment”) is entered into as of October 22, 2019, by and among SILICON VALLEY BANK, a California corporation (“Bank”), as collateral agent (in such capacity, “Collateral Agent”), Bank in its capac

Consulting and Independent Contractor Agreement, by and between the Registrant and Brion Raymond, dated as of January 3, 2020.

Exhibit 10.32 CONSULTING AND INDEPENDENT CONTRACTOR AGREEMENT THIS CONSULTING AND INDEPENDENT CONTRACTOR AGREEMENT (“Agreement”) is made by and between Clearside Biomedical, Inc., a Delaware corporation (the “Company” or “Clearside”), and Brion Raymond (“Consultant”) (hereinafter collectively “the parties”) and entered into as of the date of execution by both parties (the “Effective Date”). WHEREA

Common Stock

Filed Pursuant to Rule 424(b)(5) Registration No. 333-219132 AMENDMENT NO. 1 DATED MARCH 13, 2020 To Prospectus Supplement Dated March 15, 2019 (To Prospectus Dated July 13, 2017) $50,000,000 Common Stock This Amendment No. 1 to Prospectus Supplement, or this Amendment, amends our prospectus supplement dated March 15, 2019, or the Prospectus Supplement, and the prospectus dated July 13, 2017, or t

Third Amendment to Second Amended and Restated Loan and Security Agreement, by and between the Registrant and Silicon Valley Bank, dated as of October 18, 2019.

Exhibit 10.23 THIRD AMENDMENT TO SECOND AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT THIS THIRD AMENDMENT to Second Amended and Restated Loan and Security Agreement (this “Amendment”) is entered into as of October 18, 2019, by and among SILICON VALLEY BANK, a California corporation (“Bank”), as collateral agent (in such capacity, “Collateral Agent”), Bank in its capacity as a Lender, and the o

Entry into a Material Definitive Agreement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8‑K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2020 Clearside Biomedical, Inc.

Description of Common Stock of Clearside Biomedical, Inc. (incorporated herein by reference to Exhibit 4.4 to the Registrant’s Annual Report on Form 10-K (File No. 001-37783), filed with the Commission on March 13, 2020).

Exhibit 4.4 DESCRIPTION OF CLEARSIDE BIOMEDICAL, INC. COMMON STOCK The following description of the common stock of Clearside Biomedical, Inc., or the Company, and certain provisions of the Company’s amended and restated certificate of incorporation, or the restated certificate, and amended and restated bylaws, or restated bylaws, are summaries. These summaries are qualified in the entirety by ref

Form 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37783 Clearside Biomedical, Inc.

Separation Agreement, by and between the Registrant and Brion Raymond, dated as of January 3, 2020.

Exhibit 10.31 RELEASE AND SETTLEMENT AGREEMENT This Release and Settlement Agreement (“Agreement”) is entered into by and between Clearside Biomedical, Inc., a Delaware corporation (the “Company”), and Brion Raymond (“Employee”) (collectively, the “Parties”). WHEREAS, this Agreement provides the Employee with good and valuable consideration provided that the Employee first signs, and does not revo

License Agreement, by and between the Registrant and Bausch Health Ireland Limited, dated as of October 22, 2019 (incorporated herein by reference to Exhibit 10.26 to the Registrant’s Annual Report on Form 10-K (File No. 001-37783), filed with the Commission on March 13, 2020).

Exhibit 10.26 LICENSE AGREEMENT This License Agreement (this “Agreement”) is made as of October 22, 2019 (the “Effective Date”), by and between Clearside Biomedical, Inc., a Delaware corporation having a place of business at 900 North Point Parkway, Suite 200, Alpharetta, GA 30005, United States of America (“Clearside”), and Bausch Health Ireland Limited, an Irish company having an office at 3013

Separation Agreement, by and between the Registrant and Daniel White, dated as of April 7, 2019.

Exhibit 10.29 April 24, 2019 Daniel H. White XXXXX Re:Separation Agreement Dear Daniel: This letter sets forth the substance of the separation agreement (the “Agreement”) which Clearside Biomedical, Inc. (the “Company”) is offering to you to aid in your employment transition and which was originally provided to you on April 7, 2019. The Amended and Restated Executive Employment Agreement effective

Clearside Biomedical Announces Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update - IND Submission for CLS-AX (axitinib injectable suspension) On Track for Mid-2020 - - Greater China Licensing Partnership and Updated ND

Exhibit 99.1 Clearside Biomedical Announces Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update - IND Submission for CLS-AX (axitinib injectable suspension) On Track for Mid-2020 - - Greater China Licensing Partnership and Updated NDA Resubmission Timeline for XIPERE™ (triamcinolone acetonide suprachoroidal injectable suspension) - - Partners Expected to Initiate Clin

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8‑K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 11, 2020 Clearside Biomedical, Inc.

Joint Filing Statement Pursuant to Rule 13d-1(k)(1)

Exhibit 1 Joint Filing Statement Pursuant to Rule 13d-1(k)(1) The undersigned hereby consent and agree to the joint filing of Schedule 13G Amendment No.

CLSD / Clearside Biomedical, Inc. / RTW INVESTMENTS, LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.

CLSD / Clearside Biomedical, Inc. CORRESP - -

January 15, 2020 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Mail Stop 4546 Washington, D.C. 20549 Attn:Tim Buchmiller Re:Clearside Biomedical, Inc. Registration Statement on Form S-3 Filed January 10, 2020 File No. 333-235880 Acceleration Request Requested Date:January 17, 2020 Requested Time:4:00 P.M. Eastern Time Ladies and Gentlemen: In

CLSD / Clearside Biomedical, Inc. S-3 - - S-3

Table of Contents As filed with the Securities and Exchange Commission on January 10, 2020 Registration No.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8‑K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 30, 2019 Clearside Biomedical, Inc.

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8‑K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 17, 2019 Clearside Biomedical, Inc.

CLSD / Clearside Biomedical, Inc. / Hatteras Venture Advisors III, LLC - SC 13D/A Activist Investment

SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 5)* Under the Securities Exchange Act of 1934 CLEARSIDE BIOMEDICAL, INC. (Name of Issuer) Common Stock, $0.001 Par Value (Title of Class of Securities) 185063 10 4 (CUSIP Number) Clay Thorp 280 S. Mangum Street, Suite 350 Durham, North Carolina 27701 (919) 484-0730 (Name, Address and Teleph

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8‑K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 22, 2019 Clearside Biomedical, Inc.

Registration Rights Agreement, by and among the Registrant and the Investors named therein, dated as of November 22, 2019 (incorporated herein by reference to Exhibit 10.2 to the Registrant’s Current Report on Form 8-K (File No. 001-37783), filed with the Commission on November 25, 2019).

Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of November 22, 2019 by and among Clearside Biomedical, Inc., a Delaware corporation (the “Company”), and the “Investors” named in that certain Securities Purchase Agreement by and among the Company and the Investors (the “Purchase Agreement”). Capitalized terms used herein

Securities Purchase Agreement, dated November 22, 2019, by and among the Company and the other parties thereto.

Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of November 22, 2019 by and among Clearside Biomedical, Inc., a Delaware corporation (the “Company”), and the Investors identified on Exhibit A attached hereto (each an “Investor” and collectively the “Investors”). Recitals A.The Company and the Investors are executing and d

Forward-Looking Statements This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “int

Corporate Presentation | November 2019 Exhibit 99.1 Forward-Looking Statements This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar e

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8‑K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 20, 2019 Clearside Biomedical, Inc.

Consent and Second Amendment to Second Amended and Restated Loan and Security Agreement, by and between the Registrant and Silicon Valley Bank, dated as of August 29, 2019.

EXHIBIT 10.1 CONSENT AND SECOND AMENDMENT TO SECOND AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT THIS CONSENT AND SECOND AMENDMENT to Second Amended and Restated Loan and Security Agreement (this “Amendment”) is entered into as of August 29, 2019, by and among SILICON VALLEY BANK, a California corporation (“Bank”), as collateral agent (in such capacity, “Collateral Agent”), Bank in its capacit

September 30, 2019

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37783 Clearside Biomedical, Inc.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8‑K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2019 Clearside Biomedical, Inc.

Clearside Biomedical Announces Third Quarter 2019 Financial Results and Provides Corporate Update – Recent Partnerships Support the Broad Applicability of Suprachoroidal Space Injection Platform to Potentially Treat Multiple Ocular Diseases – – Supra

Exhibit 99.1 Clearside Biomedical Announces Third Quarter 2019 Financial Results and Provides Corporate Update – Recent Partnerships Support the Broad Applicability of Suprachoroidal Space Injection Platform to Potentially Treat Multiple Ocular Diseases – – Suprachoroidal Axitinib IND Submission Targeted for Mid-2020 – – Management to Host Webcast and Conference Call Today at 4:30 P.M. ET – ALPHAR

Entry into a Material Definitive Agreement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8‑K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 18, 2019 Clearside Biomedical, Inc.

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8‑K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 18, 2019 Clearside Biomedical, Inc.

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8‑K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 4, 2019 Clearside Biomedical, Inc.

CLSD / Clearside Biomedical, Inc. / RTW INVESTMENTS, LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.

Joint Filing Statement Pursuant to Rule 13d-1(k)(1)

Exhibit 1 Joint Filing Statement Pursuant to Rule 13d-1(k)(1) The undersigned hereby consent and agree to the joint filing of Schedule 13G under the Securities Exchange Act of 1934, as amended, with respect to the Common Stock of Clearside Biomedical, Inc.

REGENXBIO Announces Exclusive Worldwide Option and License Agreement with Clearside Biomedical for Evaluation of In-Office Delivery Platform for RGX-314

Exhibit 99.1 REGENXBIO Announces Exclusive Worldwide Option and License Agreement with Clearside Biomedical for Evaluation of In-Office Delivery Platform for RGX-314 • REGENXBIO expands RGX-314 gene therapy program to evaluate Clearside’s proprietary, in-office SCS MicroinjectorTM platform targeting suprachoroidal space delivery • Recent publication in The Journal of Clinical Investigation highlig

Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8‑K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 29, 2019 Clearside Biomedical, Inc.

Clearside Biomedical Provides New Drug Application Update for XIPERETM (triamcinolone acetonide suprachoroidal injectable suspension)

Exhibit 99.1 Clearside Biomedical Provides New Drug Application Update for XIPERETM (triamcinolone acetonide suprachoroidal injectable suspension) ALPHARETTA, Ga., August 22, 2019 - Clearside Biomedical, Inc. (Nasdaq:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today